Estimating risk of rapid disease progression in pediatric patients with autosomal dominant polycystic kidney disease: a randomized trial of tolvaptan

被引:0
作者
Djalila Mekahli
Lisa M. Guay-Woodford
Melissa A. Cadnapaphornchai
Stuart L. Goldstein
Ann Dandurand
Huan Jiang
Pravin Jadhav
Laurie Debuque
机构
[1] KU Leuven,PKD Research Group, Laboratory of Ion Channel Research, Department of Cellular and Molecular Medicine
[2] University Hospital of Leuven,Department of Pediatric Nephrology
[3] Children’s National Research Institute,Center for Translational Research
[4] Rocky Mountain Hospital for Children at Presbyterian/St. Luke’s Medical Center,Rocky Mountain Pediatric Kidney Center
[5] University of Cincinnati School of Medicine,Center for Acute Care Nephrology, Cincinnati Children’s Hospital Medical Center
[6] Cerevel Therapeutics,undefined
[7] Otsuka Pharmaceutical Development & Commercialization,undefined
[8] Inc.,undefined
[9] MDCI Biosciences LLC,undefined
来源
Pediatric Nephrology | 2024年 / 39卷
关键词
Autosomal dominant polycystic kidney disease; ADPKD; Chronic kidney disease; Risk assessment; Kidney volume; Pediatric; Tolvaptan;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1481 / 1490
页数:9
相关论文
共 194 条
[1]  
De Rechter S(2017)Is autosomal dominant polycystic kidney disease becoming a pediatric disorder? Front Pediatr 5 272-726
[2]  
Breysem L(2019)International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people Nat Rev Nephrol 15 713-2443
[3]  
Mekahli D(2011)Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease Clin J Am Soc Nephrol 6 2439-1660
[4]  
Gimpel C(1994)The spectrum of autosomal dominant polycystic kidney disease in children J Am Soc Nephrol 4 1654-1129
[5]  
Bergmann C(2012)Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation Kidney Int 82 1121-1147
[6]  
Bockenhauer D(2016)Hypertension in autosomal dominant polycystic kidney disease: a meta-analysis Arch Dis Child 101 1142-537
[7]  
Helal I(2015)Understanding the physical and emotional impact of early-stage ADPKD: experiences and perspectives of patients and physicians Clin Kidney J 8 531-1021
[8]  
Reed B(2019)Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial Eur J Pediatr 178 1013-46
[9]  
McFann K(2023)Tolvaptan for children and adolescents with autosomal dominant polycystic kidney disease: randomized controlled trial Clin J Am Soc Nephrol 18 36-487
[10]  
Yan XD(2022)The wind of change in the management of autosomal dominant polycystic kidney disease in childhood Pediatr Nephrol 37 473-951